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Summary In the first part of this study the availability of folinic acid (FA) and its main active circulating
metabolite, 5-methyltetrahydrofolate (5-MTHF), were studied in plasma and cerebrospinal fluid (CSF) from
normal subjects after i.v. administration of 100 and 250mg of FA. 5-MTHF rapidly appeared in plasma, the
maximum value being reached at the first observation time point (1 h). FA was eliminated in plasma more
slowly than 5-MTHF. Between the two doses, there was no evidence of modification in pharmacokinetic
parameters (terminal half-life, clearance) for either FA or 5-MTHF in plasma and CSF; 5-MTHF was the
only product detectable in CSF. Considering FA plus 5-MTHF together, the AUC (area under the curve)
ratios between CSF and plasma were close to 1%. 5-MTHF was cleared very slowly from CSF (t1/2 =85 h).
This finding suggested possible accumulation of 5-MTHF in CSF during repeated administration of FA
combined with medium or high dose MTX. In the second part of the study, dealing with a group of eight
children treated by such protocols, an increase in CSF 5-MTHF was detected from cycle to cycle in five
(r=0.91, P<0.01) with a maximum at 5 x 10-8 M. This progressive accumulation of 5-MTHF in CSF may
have a negative effect on the local action of MTX and should be taken into account for therapeutic strategies
designed for the management of meningeal leukaemia.
Central nervous system (CNS) involvement remains a critical
problem in the therapeutic management of malignant non-
Hodgkin's lymphomas (Mackintosh et al., 1982) and acute
lymphoblastic leukaemia (Duttera et al., 1973). Chemo-
therapy using methotrexate (MTX), associated (Freeman et
al., 1983) or not (Balis et al., 1985) with intrathecal
injections, may be effective in eradicating or preventing
meningeal diseases. High dose MTX is increasingly used in
place of radiotherapy (Brouwers et al., 1987), particularly for
preventive purposes. MTX concentrations in cerebrospinal
fluid (CSF) are critical: abnormally high levels are associated
with leukoencephalopathy (Allen et al., 1980) while low
concentrations (below a threshold of 10-6 M) are thought to
be ineffective (Hryniuk & Bertino, 1969). Folinic acid (FA),
the antidote of MTX, is classically given in conjunction with
medium or high-dose MTX; its administration is repeated
until the blood MTX level drops below 10-8 M (Bertino,
1981).
Information on the behaviour of FA and its active
metabolite 5-methyltetrahydrofolate (5-MTHF) in CSF is
necessary for evaluation of (i) the potential effects of FA
rescue in CSF for a given systemic dose of this antidote and,
particularly, (ii) the possibility of adverse accumulation of
FA and/or 5-MTHF in CSF, which might inhibit MTX
cytotoxic effects in CSF during MTX cycles with relatively
short intervals. Straw et al. (1984) reported on the plasma
pharmacokinetics of FA and 5-MTHF for doses between 25
and 100 mg. In the first part of the present study we
evaluated the pharmacokinetics of FA and 5-MTHF in both
plasma and CSF for healthy subjects in a higher dose range
(100-250mg). Combined with the findings of Straw et al.
(1984), our study covers the FA dose range generally
prescribed to patients (Jolivet et al., 1983). For obvious
ethical and technical reasons repeated lumbar punctures are
not possible on patients. Therefore healthy consenting adults
were included with one FA dose and one CSF sampling time
per subject. Several subjects were thus tested for each
concentration-time point in order to obtain representative
mean concentration-time points.
The demonstration of a prolonged retention of 5-MTHF
in CSF led us to pursue these investigations by determining,
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in the second part of the study, the reduced folate levels in
CSF for a group of eight children with acute lymphocytic
leukaemia treated by MTX plus FA rescue.
Materials and methods
Study population
There were two groups: one group (G1) of 28 evaluable,
ambulatory normal volunteers (17 males, 11 females) with a
mean age of 42.5 years (23-77) admitted for diagnostic
radiculography in the Neurosurgery Department of the
Hopital Pasteur (Nice, France). All subjects had given their
informed consent. FA (Lederfoline Lederle, France) was
injected by i.v. bolus. Each patient received a specific dose of
FA; samples (concomitant blood and CSF) were obtained at
fixed times after FA injection: 1, 2, 6, 12 and 24h. It was
not possible to hospitalise these ambulatory subjects for
more than 24h. Attempts were made to test several subjects
per time point at each dose. The other group (G2) was the
patients group. It consisted of eight patients (six males and
two females) with acute lymphocytic leukaemia, mean age 5
years (2-9), without signs of meningeal disease. They were
treated by MTX (2.5 gm-2) and FA rescue according to the
EORTC Children's Leukaemia Cooperative group protocol
which follows the general guidelines of the BFM protocol
(Riehm et al., 1980). CSF samples were obtained 8 h after
the beginning of the 24-h administration of MTX and just
before injection of the intrathecal MTX dose. Courses were
administered at a 2-week interval. CSF (1-2ml) and blood
(3-5 ml) were collected in EDTA tubes. Ascorbic acid
(2mgml-1) was added immediately to stabilise the samples.
Blood was centrifuged for 10min at 2,500r.p.m. Plasma and
CSF were stored at -20°C until analysed.
FA and 5-MTHF analysis
Stock solutions (10-3 M in saline) were prepared for FA
(Specia, France), 5-MTHF (Sigma, France) and the internal
standard (IS): paraaminoacetophenone (10-3 M in methanol,
Sigma). They were stored at -20°C. An original method
based on the extraction procedure was developed. Briefly,
1 ml CSF or plasma (patients or blanks spiked with known
amounts of FA, 5-MTHF and IS) was eluted through an
extraction cartridge (Sep-Pak C18, Millipore, Waters,
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France) activated by successive passages of 2ml methanol,
2 ml H20, and 3 ml Tris 0.1 M, pH=7.00. The cartridge was
rinsed with 750pl of Tris, pH=7.00, and eluted with 2ml of
a mixture of methanol 75% and Tris 25%, pH=7.00. The
first 250,pl was discarded and the remaining eluate was
collected and evaporated during 45 min at 37°C under a
stream of nitrogen. Dried residues were dissolved in 250p1 of
HPLC buffer, pH=7.00. Samples were centrifuged at 4°C
for 10 min at 2,500 r.p.m., and 25pl of the supernatant was
injected in the HPLC system.
FA, 5-MTHF and IS were chromatographed on a Merck
Hibar-Lichrocart column 125x4mm C18 5 pm (Merck ref
50825. France). The liquid phase was Methanol/H20 (30/70)
with one flask per litre of peakA low UV (Millipore, Waters
ref. 610471, France) adjusted with H3PO4 to pH=7.00.
Flow rate was 1 ml min-. Products were detected by UV
absorption at 313 nM (Kratos 783, France). Respective peaks
for FA, 5-MTHF and IS were calculated with an HP 3390A
integrator (Hewlett-Packard) according to peak height. FA,
IS and 5-MTHF were completely separated within 7min.
Between 1 x 10-7 M and 2.5 x 10- M, peak heights increased
linearly with the concentration (r=0.99 for both FA and 5-
MTHF). Intra-assay reproducibility (n=6) was 5% for FA
and 10% for 5-MTHF; inter-assay reproducibility (n=6) was
8% for FA and 12% for 5-MTHF. The limit of sensitivity
was 1 X 10-8 M (noise x 3, 1 x 10-3 DO full scale) in plasma
and CSF for both FA and 5-MTHF.
Results
Table I Pharmacokinetic parameters of FA and 5-MTHF in Gl
Plasma CSF
Kinetic parameters 100mg 250mg 100mg 250mg
FA
tl/2(h)a 19 17
CL(I h- 1)b 0.90 1.00
AUCO24h(10- 7M h)C 2,040 4,084
SMHTF
t1/2(h) 5.1 5.0 85.2 n.e.
AUCo-24h (0M h) 266 611 18 55
at1/2, terminal half-life calculated by regression analysis with
concentration-time points at 6, 12 and 24h except for FA, calculated
between 12 and 24h.
b ~~~~~~dose bCL, total body clearance: AUC
AUCO-e=AUCO24h+AUC24h-a-
AUC24h-a= p
0.693
= tl2#
cRegression analysis with 0, AUC1OOmg, AUC250mg-
For FA in plasma: AUC= 160.4+ 16.1 dose
r=0.99, P<0.01.
For 5-MTHF in plasma: AUC=8.5+2.4 dose
r=1, P<0.001.
For 5-MTHF in CSF: AUC= 1.6+0.2 dose
r=0.99, P<0.01.
n.e., non-evaluable.
Figure 1 shows the respective time-concentration profiles
(unchanged FA and its active metabolite 5-MTHF) for the
two FA i.v. doses studied. 5-MTHF quickly appears in
plasma, reaching maximal value at the first observation
point (1 h). In plasma, FA is cleared more slowly than 5-
MTHF; FA was never detected in CSF. 5-MTHF was
present in this biological fluid: the maximum concentration
was noted 6 h after systemic administration of FA. 5-MTHF
was eliminated more slowly from CSF than from plasma.
The effects of increasing FA doses on pharmacokinetic
parameters are shown in Table I. The clearance and
elimination half-life of FA were not particularly modified by
the FA dose. The AUC of FA in plasma and 5-MTHF in
both plasma and CSF rose proportionally to the FA dose.
The AUC ratios for 100 and 250mg were respectively 0.13
and 0.15 between 5-MTHF and FA in plasma, 0.07 and 0.09
for 5-MTHF between CSF and plasma, and 0.009 and 0.013
between 5-MTHF in LCR and FA in plasma. For all folates
(FA plus 5-MTHF), the ratios between CSF and plasma
were 0.008 for 100mg and 0.012 for 250mg.
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Figure 2 Evolution of CSF 5-MTHF from cycle to cycle in G2.
Dashed line=lowest concentration detectable (1 x 10-8 M).
Values below the detection limit have been indicated to show
that samples were effectively measured but in these cases the
concentrations were not evaluable.
Figure 2 shows the evolution from cycle to cycle of 5-
MTHF in CSF of eight children with ALL treated by MTX
plus FA rescue. In all CSF samples FA was never detectable.
In 7/8 patients, 5-MTHF was detected in CSF and in 5/8
cases there was a progressive accumulation of 5-MTHF in
CSF (r=0.91, P<0.01) with a maximum value of
5 x 10-8M.
Discussion
An adequate concentration of FA is necessary to neutralise
... A ., -P' -., P 'a' lr" r .1 r .s . .
0 6 12 18 24 unwanted cytotoxic ettects ot MTX; the optimal time
Hours interval between the end of MTX administration and the start of FA rescue has still not been objectively defined
FA and 5-MTHF in (Jolivet et al., 1983). Both in vitro investigations (Browman
lues. 0, FA in plasma; et al., 1985) and pharmacokinetic studies on FA are required
CSF. to obtain such information. CNS involvement in non-
IEVIDENCE FOR CSF ACCUMULATION OF 5-METHYLTETRAHYDROFOLATE 629
Hodgkin's lymphoma and acute lymphocytic leukaemia may
be prevented or treated by repeated medium or high dose
MTX combined with FA rescue (Freeman et al., 1983; Balis
et al., 1985). Data were missing on the possibility of an
adverse accumulation of FA in CSF in such protocols; in
addition, as dihydrofolate reductase is present in the brain
(Pollock & Kaufman, 1978), information is required on the
appropriate systemic FA dose for neutralisation of excessive
MTX exposure in CSF (Cohen et al., 1986). The findings of
the present study may help to clarify these points. The
improved analytical method we used allows rapid, specific
and sensitive measurement of FA and its main circulating
metabolite in plasma and CSF. The kinetics of stereoisomers
of unchanged FA has been dealt with by Straw et al. (1984)
but is not central in this work and, moreover, 5-MTHF is
not compromised by this stereochemistry. In light of the
findings of a previous study (Payet et al., 1987), FA kinetics
appear to be the same in both cancer patients and healthy
volunteers, making extrapolation of the present results
obtained in healthy subjects to cancer patients under MTX
treatment acceptable.
The values of the main pharmacokinetic parameters
determined in the first part of the study for FA and 5-
MTHF closely agree with those reported by the previously
mentioned authors. 5-MTHF appears rapidly in plasma, the
maximum value occurring at the initial time point (1 h).
Results agree with previous reports of maximum plasma FA
concentration at 1 h (Hamel et al., 1981) or 1-2 h (Payet et
al., 1987). In the present study FA was eliminated in plasma
more slowly than 5-MTHF. In healthy volunteers, Payet et
al. (1987) noted terminal half-lives of 7.0 and 1.9h for FA
and 5-MTHF respectively during a 12 h post-injection
period. Herein, during a 24h survey period, the difference
between the slopes of elimination of these two products was
more marked: 5-MTHF half-life was 3-4 times shorter than
that of FA. The two FA doses studied (100 and 250mg) did
not modify the pharmacokinetic parameters of FA and 5-
MTHF in plasma and CSF. This is strengthened by the
AUC rise in parallel to the dose (Table I). FA kinetics thus
appear linear between 100 and 250mg. This information
complements similar data on FA linearity between 25 and
100mg (Straw et al., 1984). 5-MTHF was the only folate
detectable in CSF during systemic administration of FA
(Mehta et al., 1979). It appears clearly that only 5-MTHF
reaches the CSF (Figure 1). In cases of acute neurological
dysfunction due to high-dose MTX (Packer et al., 1983),
specific MTX CNS rescue would probably be best achieved
by using the stable preparation of 5-MTHF now available
(Reggev & Djerassi, 1986). When classical rescue by FA is
used, oral administration would also appear better indicated
because 5-MTHF is more bioavailable by this route than
after i.m. or i.v. administration (McGuire et al., 1986). For
all folates considered together (FA plus 5-MTHF) the AUC
ratios between CSF and plasma were approximately 1%.
This value is comparable to the passage of MTX from
plasma to CSF that other authors (Borsi & Moe, 1987) and
ourselves (Thyss et al., 1987) have established as being very
close to 1%. But disappearance of MTX from CSF is much
more rapid (6.6 h: Bode et al., 1980) than that found herein
for 5-MTHF. Consequently, and this is the central point of
this work, during repeated sequential administrations of FA,
5-MTHF might accumulate in CSF, the potential risk being
an inhibition of further MTX '.-tion in this compartment.
This hypothetical situation might be encountered during
administration of chemotherapy for childhood ALL using
MTX plus FA rescue (Riehm et al., 1980) with repeated
courses at short-term intervals. We thus checked the
evolution of CSF folates in a limited series of eight children
treated by a similar protocol. None of them had a meningeal
involvement with their disease. The absence of detectable
unchanged FA in CSF in healthy subjects has been
confirmed in these patients. Levels of 5-MTHF were
detectable for 7/8 patients. For five of them CSF 5-MTHF
concentrations increased during treatment courses (up to
5 x 10-8 M). Standard doses (0.5 gm-2) and high doses
(2.5 gm-2) of MTX generate median MTX CSF values of
8 x 10-8 M and 6 x I0-7 M respectively (Thyss et al., 1987).
Diddens et al. (1987) established in a lymphoblastoid cell line
that the cytotoxic effect of high concentrations of MTX was
reversed by relatively low concentrations of simultaneously
added leucovorin. There is thus a potential risk of
competition between folates and antifolates in CSF during
standard or even high dose MTX plus FA rescue in the
treatment of childhood ALL. The time-concentration profile
of 5-MTHF in CSF should certainly be explored in a larger
series of patients in view to strengthen our present
conclusions.
These results should allow clinicians to be aware of the
possibility of 5-MTHF accumulation in CSF and may lead
them to reconsider the design of therapy strategy in terms of
FA doses and duration of administration in order to
improve the management of meningeal leukaemia by MTX.
This work has been presented in part as a poster at the Annual
AACR Meeting, New Orleans, May 1988. Supported by
FEGEFLUC and Comite departemental du Var de la Ligue
Nationale Francaise contre le Cancer.
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